Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 3.69
BIIB's Cash to Debt is ranked lower than
66% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. BIIB: 3.69 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s 10-Year Cash to Debt Range
Min: 0.25  Med: 1.56 Max: N/A
Current: 3.69
Equity to Asset 0.77
BIIB's Equity to Asset is ranked higher than
61% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.76 Max: 0.85
Current: 0.77
0.52
0.85
Interest Coverage 134.09
BIIB's Interest Coverage is ranked lower than
84% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 134.09 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s 10-Year Interest Coverage Range
Min: 2.3  Med: 36.19 Max: 9999.99
Current: 134.09
2.3
9999.99
F-Score: 9
Z-Score: 19.05
M-Score: -2.25
WACC vs ROIC
6.73%
36.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating margin (%) 43.46
BIIB's Operating margin (%) is ranked higher than
95% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. BIIB: 43.46 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05  Med: 31.63 Max: 52.91
Current: 43.46
-128.05
52.91
Net-margin (%) 32.36
BIIB's Net-margin (%) is ranked higher than
93% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. BIIB: 32.36 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85  Med: 21.74 Max: 36.64
Current: 32.36
-128.85
36.64
ROE (%) 31.76
BIIB's ROE (%) is ranked higher than
95% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. BIIB: 31.76 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s 10-Year ROE (%) Range
Min: -21.44  Med: 17.31 Max: 31.98
Current: 31.76
-21.44
31.98
ROA (%) 23.96
BIIB's ROA (%) is ranked higher than
97% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. BIIB: 23.96 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s 10-Year ROA (%) Range
Min: -15.14  Med: 12.08 Max: 24.62
Current: 23.96
-15.14
24.62
ROC (Joel Greenblatt) (%) 181.55
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. BIIB: 181.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.49  Med: 68.87 Max: 211.79
Current: 181.55
-62.49
211.79
Revenue Growth (3Y)(%) 25.70
BIIB's Revenue Growth (3Y)(%) is ranked higher than
82% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BIIB: 25.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -13.9  Med: 23.20 Max: 84.7
Current: 25.7
-13.9
84.7
EBITDA Growth (3Y)(%) 31.90
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. BIIB: 31.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.4  Med: 31.90 Max: 86
Current: 31.9
-16.4
86
EPS Growth (3Y)(%) 34.90
BIIB's EPS Growth (3Y)(%) is ranked higher than
87% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. BIIB: 34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -66  Med: 34.90 Max: 205.2
Current: 34.9
-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIIB Guru Trades in Q2 2014

Jim Simons 129,261 sh (New)
Louis Moore Bacon 32,500 sh (New)
Stanley Druckenmiller 103,800 sh (New)
Ken Fisher 88,885 sh (+386.61%)
Jeremy Grantham 857,799 sh (+79.83%)
Ron Baron 8,632 sh (+41.76%)
Mario Gabelli 4,175 sh (+16.46%)
Frank Sands 4,891,463 sh (+0.38%)
Murray Stahl 8,493 sh (unchged)
Steven Cohen 7,600 sh (unchged)
Bill Frels 1,125 sh (unchged)
Ken Heebner Sold Out
Joel Greenblatt Sold Out
George Soros Sold Out
John Burbank Sold Out
Caxton Associates Sold Out
Andreas Halvorsen Sold Out
PRIMECAP Management 17,258,311 sh (-1.39%)
Pioneer Investments 1,232 sh (-1.52%)
Vanguard Health Care Fund 559,700 sh (-6.62%)
RS Investment Management 16,250 sh (-8.04%)
Paul Tudor Jones 899 sh (-72.75%)
» More
Q3 2014

BIIB Guru Trades in Q3 2014

Joel Greenblatt 31,391 sh (New)
Ken Heebner 80,000 sh (New)
Ray Dalio 1,646 sh (New)
Paul Tudor Jones 3,061 sh (+240.49%)
RS Investment Management 20,205 sh (+24.34%)
Mario Gabelli 4,635 sh (+11.02%)
Bill Frels 1,170 sh (+4.00%)
Frank Sands 4,952,096 sh (+1.24%)
Pioneer Investments 1,069 sh (unchged)
Stanley Druckenmiller 103,800 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Ron Baron 8,613 sh (-0.22%)
PRIMECAP Management 17,216,631 sh (-0.24%)
Murray Stahl 8,468 sh (-0.29%)
Jeremy Grantham 800,301 sh (-6.70%)
Ken Fisher 78,457 sh (-11.73%)
Jim Simons 92,661 sh (-28.31%)
Vanguard Health Care Fund 233,600 sh (-58.26%)
» More
Q4 2014

BIIB Guru Trades in Q4 2014

Pioneer Investments 18,593 sh (+1639.29%)
Ray Dalio 15,146 sh (+820.17%)
Paul Tudor Jones 27,786 sh (+807.74%)
Stanley Druckenmiller 359,400 sh (+246.24%)
Mario Gabelli 4,935 sh (+6.47%)
Ron Baron 9,144 sh (+6.17%)
Ken Fisher 79,254 sh (+1.02%)
Murray Stahl 8,517 sh (+0.58%)
Frank Sands 4,974,331 sh (+0.45%)
Frank Sands 4,974,331 sh (+0.45%)
Ken Heebner Sold Out
Vanguard Health Care Fund Sold Out
PRIMECAP Management 17,170,693 sh (-0.27%)
Bill Frels 1,140 sh (-2.56%)
Jeremy Grantham 696,116 sh (-13.02%)
Jim Simons 65,161 sh (-29.68%)
Joel Greenblatt 5,012 sh (-84.03%)
RS Investment Management 1,218 sh (-93.97%)
» More
Q1 2015

BIIB Guru Trades in Q1 2015

John Burbank 46,268 sh (New)
Steven Cohen 8,800 sh (New)
Richard Snow 2,500 sh (New)
Signature Select Canadian Fund 5,500 sh (New)
Vanguard Health Care Fund 339,100 sh (New)
RS Investment Management 27,197 sh (+2132.92%)
Ray Dalio 20,446 sh (+34.99%)
Ken Fisher 81,058 sh (+2.28%)
Frank Sands 5,009,615 sh (+0.71%)
Ron Baron 9,144 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 4,932 sh (-0.06%)
Pioneer Investments 18,472 sh (-0.65%)
Murray Stahl 8,448 sh (-0.81%)
Bill Frels 1,120 sh (-1.75%)
PRIMECAP Management 16,558,763 sh (-3.56%)
Jeremy Grantham 669,145 sh (-3.87%)
Stanley Druckenmiller 175,000 sh (-51.31%)
Jim Simons 30,300 sh (-53.50%)
Paul Tudor Jones 4,880 sh (-82.44%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Inc

PRIMECAP Sells Portions of Its Top Two Stakes
Pasadena, California-based PRIMECAP Management (Trades, Portfolio) was founded in September 1983 as an independent investment management company. It evaluates securities based on their outlook over three to five years, longer if warranted. The Vanguard PRIMECAP Fund, one of the funds it manages, logged a return of 18.72% in 2014. Read more...
Ken Fisher's Top Increases of the Second Quarter
CEO and CIO of Fisher Investments and regular Forbes contributor, Ken Fisher, had a pretty busy second quarter. Fisher purchased a total of 50 new stocks. His second quarter portfolio holds 558 stocks and is valued at over $47.56 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings during the second quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.15
BIIB's P/E(ttm) is ranked higher than
62% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 41.10 vs. BIIB: 29.15 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74  Med: 29.00 Max: 1121.33
Current: 29.15
11.74
1121.33
PE(NRI) 29.50
BIIB's PE(NRI) is ranked higher than
61% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 37.80 vs. BIIB: 29.50 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s 10-Year PE(NRI) Range
Min: 11.73  Med: 29.00 Max: 1085.16
Current: 29.5
11.73
1085.16
P/B 8.14
BIIB's P/B is ranked lower than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. BIIB: 8.14 )
Ranked among companies with meaningful P/B only.
BIIB' s 10-Year P/B Range
Min: 1.74  Med: 3.15 Max: 9.6
Current: 8.14
1.74
9.6
P/S 9.44
BIIB's P/S is ranked higher than
60% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. BIIB: 9.44 )
Ranked among companies with meaningful P/S only.
BIIB' s 10-Year P/S Range
Min: 2.8  Med: 6.09 Max: 11.93
Current: 9.44
2.8
11.93
PFCF 29.55
BIIB's PFCF is ranked higher than
57% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 33.86 vs. BIIB: 29.55 )
Ranked among companies with meaningful PFCF only.
BIIB' s 10-Year PFCF Range
Min: 10.04  Med: 23.56 Max: 169.92
Current: 29.55
10.04
169.92
POCF 26.79
BIIB's POCF is ranked higher than
55% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 31.61 vs. BIIB: 26.79 )
Ranked among companies with meaningful POCF only.
BIIB' s 10-Year POCF Range
Min: 7.83  Med: 18.30 Max: 42.19
Current: 26.79
7.83
42.19
EV-to-EBIT 21.37
BIIB's EV-to-EBIT is ranked higher than
67% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. BIIB: 21.37 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s 10-Year EV-to-EBIT Range
Min: -21.4  Med: 21.00 Max: 585.7
Current: 21.37
-21.4
585.7
PEG 1.16
BIIB's PEG is ranked higher than
79% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. BIIB: 1.16 )
Ranked among companies with meaningful PEG only.
BIIB' s 10-Year PEG Range
Min: 0.33  Med: 1.15 Max: 2.56
Current: 1.16
0.33
2.56
Shiller P/E 57.65
BIIB's Shiller P/E is ranked lower than
54% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 48.91 vs. BIIB: 57.65 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s 10-Year Shiller P/E Range
Min: 24.2  Med: 62.74 Max: 1337
Current: 57.65
24.2
1337
Current Ratio 2.70
BIIB's Current Ratio is ranked lower than
66% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BIIB: 2.70 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s 10-Year Current Ratio Range
Min: 0.78  Med: 3.53 Max: 17.39
Current: 2.7
0.78
17.39
Quick Ratio 2.28
BIIB's Quick Ratio is ranked lower than
67% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BIIB: 2.28 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s 10-Year Quick Ratio Range
Min: 0.7  Med: 3.12 Max: 16.79
Current: 2.28
0.7
16.79
Days Inventory 228.61
BIIB's Days Inventory is ranked lower than
77% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. BIIB: 228.61 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s 10-Year Days Inventory Range
Min: 69.41  Med: 238.11 Max: 10720.03
Current: 228.61
69.41
10720.03
Days Sales Outstanding 50.09
BIIB's Days Sales Outstanding is ranked higher than
62% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. BIIB: 50.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s 10-Year Days Sales Outstanding Range
Min: 4.44  Med: 45.99 Max: 106.69
Current: 50.09
4.44
106.69

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 55.76
BIIB's Price/Net Current Asset Value is ranked lower than
94% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. BIIB: 55.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.59  Med: 23.65 Max: 789.6
Current: 55.76
0.59
789.6
Price/Tangible Book 17.40
BIIB's Price/Tangible Book is ranked lower than
85% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. BIIB: 17.40 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s 10-Year Price/Tangible Book Range
Min: 0.41  Med: 6.33 Max: 48.16
Current: 17.4
0.41
48.16
Price/Projected FCF 3.47
BIIB's Price/Projected FCF is ranked higher than
55% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIIB: 3.47 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s 10-Year Price/Projected FCF Range
Min: 0.65  Med: 2.06 Max: 25.99
Current: 3.47
0.65
25.99
Price/DCF (Earnings Based) 1.04
BIIB's Price/DCF (Earnings Based) is ranked higher than
69% of the 13 Companies
in the Global Biotechnology industry.

( Industry Median: 1.21 vs. BIIB: 1.04 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.55
BIIB's Price/Median PS Value is ranked lower than
64% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BIIB: 1.55 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 0.95 Max: 12.71
Current: 1.55
0.12
12.71
Price/Peter Lynch Fair Value 1.17
BIIB's Price/Peter Lynch Fair Value is ranked higher than
77% of the 52 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. BIIB: 1.17 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44  Med: 1.38 Max: 20.5
Current: 1.17
0.44
20.5
Price/Graham Number 4.73
BIIB's Price/Graham Number is ranked lower than
62% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. BIIB: 4.73 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s 10-Year Price/Graham Number Range
Min: 0.43  Med: 3.25 Max: 21.27
Current: 4.73
0.43
21.27
Earnings Yield (Greenblatt) (%) 4.74
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BIIB: 4.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 4.70 Max: 12
Current: 4.74
0.2
12
Forward Rate of Return (Yacktman) (%) 28.47
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.56 vs. BIIB: 28.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.8  Med: 20.20 Max: 43.9
Current: 28.47
0.8
43.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Investment Strategies for the Bullish Biotech Sector Jun 01 2015 
Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 
PRIMECAP Sells Portions of Its Top Two Stakes May 27 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
Vanguard Healthcare Fund Adds Four New Positions May 01 2015 
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Biogen And Idec To Part Ways After Inventing Alzheimer's Drug Mar 27 2015 
Biogen’s Alzheimer’s Drug Shows Promising Test Results Mar 23 2015 

More From Other Websites
Applied Genetic Up on Biogen Deal for Eye Disease Drugs - Analyst Blog Jul 03 2015
What You May Have Missed in Biotech: Celgene's $1B Bet on Cancer Immunotherapy, and a New CF Drug Jul 03 2015
Xoom Zooms, Teladoc Sinks a Day After Debut -- Tech Winners and Losers Jul 02 2015
Biogen: Where Did That Come From? Jul 02 2015
Applied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen Deal Jul 02 2015
Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments Jul 02 2015
Biogen, AGTC Link Up To Develop Gene Therapy Jul 02 2015
Biogen deal pushes tiny company’s stock up by double digits Jul 02 2015
Biogen enters eye-treatment arena with AGTC deal Jul 02 2015
Biogen Opens Gene Therapy Partnership Worth About $1 Billion Jul 02 2015
Biogen And AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology Jul 02 2015
Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology Jul 02 2015
AGTC to Host Conference Call and Webcast to Discuss Biogen Collaboration Jul 02 2015
AGTC to Host Conference Call and Webcast to Discuss Biogen Collaboration Jul 02 2015
Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology Jul 02 2015
Biogen Invests in the Greater Zurich Area: Biopharmaceutical Plant in the Canton of Solothurn... Jul 01 2015
U.S. doctors, hospitals reap $6.5 bln from drug and device makers -report Jun 30 2015
Why is Celgene So Darn Expensive? Jun 30 2015
Why Alexion Stock Could Rip Jun 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK